Company: BIAF
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001641172-25-001840
Chunk: 529

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 3
Chunk 529
---
 operating
    activities 

    Net loss 
    $(9,039,831) 
    $(7,937,011)
  
    Adjustments to reconcile
    net loss to net cash used in operating activities: 

    Depreciation and amortization 
     605,637  
     249,592 
  
    Stock-based compensation
    expense 
     989,681  
     748,823 

    Changes in operating
    assets and liabilities: 

    Accounts and other receivables 
     (327,530) 
     311,366 
  
    Inventory 
     (9,124) 
     (12,944)
  
    Prepaid expenses and
    other assets 
     (105,594) 
     214,402 
  
    Accounts payable 
     382,521  
     (14,501)
  
    Accrued expenses 
     248,911  
     362,012 
  
    Unearned revenue 
     (8,654) 
     33,058 
  
    Accrued interest 
     —  
     — 
  
    Operating
    lease right-of-use asset 
     (812) 
     7,397 
  
    Net
    cash used in operating activities 
     (7,264,795) 
     (6,037,806)

    Cash flows from investing
    activities 

    Purchase of property
    and equipment 
     (79,083) 
     (22,902)
  
    Acquisition,
    net of cash acquired 
     —  
     (2,186,497)
  
    Net
    cash used in investing activities 
     (79,083) 
     (2,209,399)

    Cash flows from financing
    activities 

    Proceeds from issuance
    of common stock from direct offering, net of underwriting discounts, commissions, and offering expenses of $1,334,811 
     4,350,885  
     — 
  
    Proceeds from exercised
    stock options 
     74,899  
     — 
  
    Proceeds from exercise
    of warrants 
     1,371,147  
     — 
  
    Payment on loans payable 
     —  
     (251,746)
  
    Proceeds from loans